Tau PET also has been considered potentially useful for antemortem assessment of non-AD tauopathies, such as progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and some variants of frontotemporal lobar degeneration (FTLD) [44]. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.